Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Vital Therapies Says Liver Device Shows Long-term Benefit in China Trial

publication date: Oct 14, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Vital Therapies, Inc. reported that its bioartifical liver support system, ELAD, produced a significant increase in transplant-free survival. A follow-up to the original China trial, conducted at the three-year point, shows that patients who survive in the short term enjoy extended survival. In a remarkable headline statistic, the follow-up concluded that median survival of the ELAD patients was at least 3 years, while the median survival for the control group was 37 days. More details....

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...